title: Recombinant human erythropoietin and the risk of thrombosis in patients receiving thalidomide for multiple myeloma.
abstract: Among 199 patients treated with thalidomide for multiple myeloma, four thromboses occurred in 49 cases during erythropoietin therapy (prevalence 8.1%; annual rate 7.25%), and another 14 events occurred in patients not on erythropoietin (9.3%; 7.56%). Thus, erythropoietin would seem not to increase the risk of thrombosis of myeloma patients receiving thalidomide.
authors.forename: Monica
authors.initials: M
authors.lastname: Galli
authors.forename: Francesca
authors.initials: F
authors.lastname: Elice
authors.forename: Claudia
authors.initials: C
authors.lastname: Crippa
authors.forename: Benedetto
authors.initials: B
authors.lastname: Comotti
authors.forename: Francesco
authors.initials: F
authors.lastname: Rodeghiero
authors.forename: Tiziano
authors.initials: T
authors.lastname: Barbui
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D004357:Drug Synergism; D004921:Erythropoietin / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications / Q000188:drug therapy*; D011994:Recombinant Proteins; D012306:Risk; D013792:Thalidomide / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D013927:Thrombosis / Q000139:chemically induced* / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D020246:Venous Thrombosis / Q000139:chemically induced / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D014859:Warfarin / Q000627:therapeutic use
chemical_list: D000925:Anticoagulants; D000970:Antineoplastic Agents; D011994:Recombinant Proteins; D004921:Erythropoietin; D013792:Thalidomide; D014859:Warfarin